Hospira to Acquire Physiometrix

To broaden its portfolio of intensive-care and operating-room products, Hospira, Inc. (Lake Forest, IL, USA) has agreed to acquire Physiometrex (North Billerica, MA, USA) for about U.S.$23 million in cash plus the assumption of the company's debt, projected to be around $1 million.

Physiometrix's portfolio of medical devices includes the PSA 4000, an easy-to-use real-time electroencephalogram (EEG), or brain-state monitor, that features disposable sensors and a proprietary measurement parameter called the Patient State Index. These are used to monitor the effects of anesthetic agents. This enables anesthesiologists to be more precise in administering anesthesia, which can minimize the risk of under- or over-medicating a patient, reduce side effects, and help speed recovery. Physiometrix has now developed a new model, the PSA 5000, which is easier to use and can be expanded with additional functions.

"Acquiring Physiometrix and its technology supports Hospira's strategic focus on helping our customers continuously enhance patient safety and reduce costs in hospitals,” observed John Arnott, senior vice president, Global Commercial Operations, Hospira. "Physiometrix's devices complement our product line, and provide us with an entry into the fast-growing sedation-monitoring market and a core technology that could be further expanded over the long term.”

Hospira offers a broad line of products used in intensive-care units or operating rooms, including generic acute-care injectables.






Related Links:
Hospira
Physiometrix